{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T19:00:57Z","timestamp":1785006057011,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"DOI":"10.1186\/s12969-026-01235-2","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T04:08:37Z","timestamp":1783310917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Variation in the access and use of biologic and targeted synthetic DMARDs in juvenile idiopathic arthritis: insights from a national UK survey"],"prefix":"10.1186","volume":"24","author":[{"given":"Samantha","family":"Cooray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalindi","family":"Rajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Compeyrot-Lacassagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan S.","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Fell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dearbhla","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Danielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cortina-Borja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coziana","family":"Ciurtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameenat Lola","family":"Solebo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Brogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Arthritis UK Paediatric Rheumatology Clinical Studies Group (CSG), JIA Topic Specific Group and the Scottish Paediatric and Adolescent Rheumatology Network (SPARN)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"6","key":"1235_CR1","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1093\/rheumatology\/keab714","volume":"61","author":"R Costello","year":"2022","unstructured":"Costello R, McDonagh J, Hyrich KL, Humphreys JH. Incidence and prevalence of juvenile idiopathic arthritis in the United Kingdom, 2000\u20132018: results from the Clinical Practice Research Datalink. Rheumatology (Oxford). 2022;61(6):2548\u201354. https:\/\/doi.org\/10.1093\/rheumatology\/keab714.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"1235_CR2","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1002\/art.30426","volume":"63","author":"E Nordal","year":"2011","unstructured":"Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, et al. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum. 2011;63(9):2809\u201318. https:\/\/doi.org\/10.1002\/art.30426.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1235_CR3","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1136\/annrheumdis-2014-206034","volume":"75","author":"AM Selvaag","year":"2016","unstructured":"Selvaag AM, Aulie HA, Lilleby V, Flato B. Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis. Ann Rheum Dis. 2016;75(1):190\u201395. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206034.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1235_CR4","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u201392.","journal-title":"J Rheumatol"},{"issue":"1","key":"1235_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","volume":"18","author":"H Gordon","year":"2024","unstructured":"Gordon H, Burisch J, Ellul P, Karmiris K, Katsanos K, Allocca M, et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2024;18(1):1\u201337.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"1235_CR6","doi-asserted-by":"publisher","first-page":"103086","DOI":"10.1016\/j.autrev.2022.103086","volume":"21","author":"JA Storwick","year":"2022","unstructured":"Storwick JA, Brett AC, Buhler K, Chin A, Schmeling H, Johnson NA, et al. Prevalence and titres of antinuclear antibodies in juvenile idiopathic arthritis: a systematic review and meta-analysis. Autoimmun Rev. 2022;21(6):103086.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1235_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1136\/ard-2022-222849","volume":"82","author":"HI Brunner","year":"2023","unstructured":"Brunner HI, Foeldvari I, Alexeeva E, Ayaz NA, Calvo Penades I, Kasapcopur O, et al. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis. 2023;82(1):154\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"1235_CR8","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385\u201395. https:\/\/doi.org\/10.1056\/NEJMoa1112802.","journal-title":"N Engl J Med"},{"issue":"6","key":"1235_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/ard-2022-223739","volume":"82","author":"F De Benedetti","year":"2023","unstructured":"De Benedetti F, Grom AA, Brogan PA, Bracaglia C, Pardeo M, Marucci G, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis. 2023;82(6):857\u201365.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1235_CR10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810\u201320. https:\/\/doi.org\/10.1056\/NEJMoa0706290.","journal-title":"N Engl J Med"},{"key":"1235_CR11","doi-asserted-by":"publisher","unstructured":"Ramanan AV, Dick AD, Guly C, McKay A, Jones AP, Hardwick B, et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol. 2020;2(3):e135\u201341. https:\/\/doi.org\/10.1016\/S2665-9913(20)30008-4.","DOI":"10.1016\/S2665-9913(20)30008-4"},{"issue":"1","key":"1235_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12969-025-01107-1","volume":"23","author":"AV Ramanan","year":"2025","unstructured":"Ramanan AV, Dick AD, Jaki T, Caruso G, Robertson DS, Jones AP, et al. Bayesian trial of adalimumab versus secukinumab for children with juvenile idiopathic arthritis associated uveitis or chronic anterior uveitis. Pediatr Rheumatol Online J. 2025;23(1):55. https:\/\/doi.org\/10.1186\/s12969-025-01107-1.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"1235_CR13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1186\/s13063-021-05651-5","volume":"22","author":"AV Ramanan","year":"2021","unstructured":"Ramanan AV, Guly CM, Keller SY, Schlichting DE, de Bono S, Liao R, et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). Trials. 2021;22(1):689. https:\/\/doi.org\/10.1186\/s13063-021-05651-5.","journal-title":"Trials"},{"issue":"10401","key":"1235_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(23)00921-2","volume":"402","author":"AV Ramanan","year":"2023","unstructured":"Ramanan AV, Quartier P, Okamoto N, Foeldvari I, Spindler A, Fingerhutova S, et al. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. Lancet. 2023;402(10401):555\u201370.","journal-title":"Lancet"},{"issue":"25","key":"1235_CR15","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa1205099.","journal-title":"N Engl J Med"},{"issue":"10315","key":"1235_CR16","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","volume":"398","author":"N Ruperto","year":"2021","unstructured":"Ruperto N, Brunner HI, Synoverska O, Ting TV, Mendoza CA, Spindler A, et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021;398(10315):1984\u201396.","journal-title":"Lancet"},{"issue":"9636","key":"1235_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383\u201391.","journal-title":"Lancet"},{"issue":"8","key":"1235_CR18","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1136\/annrheumdis-2018-213131","volume":"77","author":"T Constantin","year":"2018","unstructured":"Constantin T, Foeldvari I, Anton J, de Boer J, Czitrom-Guillaume S, Edelsten C, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018;77(8):1107\u201317.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1235_CR19","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1136\/ard-2024-225851","volume":"83","author":"B Fautrel","year":"2024","unstructured":"Fautrel B, Mitrovic S, De Matteis A, Bindoli S, Anton J, Belot A, et al. EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease. Ann Rheum Dis. 2024;83(12):1614\u201327. https:\/\/doi.org\/10.1136\/ard-2024-225851.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1235_CR20","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/art.42037","volume":"74","author":"KB Onel","year":"2022","unstructured":"Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2022;74(4):553\u201369.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"1235_CR21","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/art.40884","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Rheumatol. 2019;71(6):846\u201363.","journal-title":"Arthritis Rheumatol"},{"key":"1235_CR22","doi-asserted-by":"publisher","unstructured":"Tucker L, Allen A, Chandler D, Ciurtin C, Dick A, Foulkes A, et al. The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. Rheumatology (Oxford). 2022;61(9):e255\u201366. https:\/\/doi.org\/10.1093\/rheumatology\/keac295.","DOI":"10.1093\/rheumatology\/keac295"},{"key":"1235_CR23","unstructured":"Cleary G, McErlane F. Paediatric rheumatology: GIRFT programme national specialty report. NHS England; 2025."},{"key":"1235_CR24","doi-asserted-by":"publisher","unstructured":"Beresford M, Baildam E, Brogan P, Foster HE, Ramanan AV, Rooney ME, et al. UK paediatric rheumatology and its clinical trials network. Pediatr Rheumatol. 2008;6(S1):6 P150. https:\/\/doi.org\/10.1186\/1546-0096-6-S1-P150.","DOI":"10.1186\/1546-0096-6-S1-P150"},{"key":"1235_CR25","unstructured":"R-Core-Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2023."},{"key":"1235_CR26","unstructured":"Jennings W. WC. Graphical visualization of polling results. The Oxford Handbook of Polling and Survey Methods; 2018."},{"key":"1235_CR27","first-page":"65","volume":"52","author":"TH Zhang J","year":"2019","unstructured":"Zhang J TH, Chen W, et al. Visualizing complex data with heat maps. J Visual Lang Comput. 2019;52:65\u201375.","journal-title":"J Visual Lang Comput"},{"issue":"43","key":"1235_CR28","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, Chang W, D\u2019Agostino McGowan L, Fran\u00e7ois R, et al. Welcome to the Tidyverse. J Sport Hist Open Source Softw. 2019;4(43):1686. https:\/\/doi.org\/10.21105\/joss.01686.","journal-title":"J Sport Hist Open Source Softw"},{"key":"1235_CR29","volume-title":"Permutation tests: a practical guide to resampling methods for testing hypotheses","author":"P Good","year":"2013","unstructured":"Good P. Permutation tests: a practical guide to resampling methods for testing hypotheses. 3rd ed. New York: Springer; 2013.","edition":"3rd"},{"key":"1235_CR30","doi-asserted-by":"crossref","unstructured":"Holt CA, Sullivan SP. Permutation tests for experimental data. Exp Econ. 2023;1\u201338.","DOI":"10.1007\/s10683-023-09799-6"},{"key":"1235_CR31","unstructured":"NHS-England. Clinical commissioning policy statement: biologic therapies for the treatment of juvenile idiopathic arthritis (JIA). 2015;1\u201316."},{"issue":"3","key":"1235_CR32","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/art.27284","volume":"62","author":"PJ Hunter","year":"2010","unstructured":"Hunter PJ, Nistala K, Jina N, Eddaoudi A, Thomson W, Hubank M, et al. Biologic predictors of extension of oligoarticular juvenile idiopathic arthritis as determined from synovial fluid cellular composition and gene expression. Arthritis Rheum. 2010;62(3):896\u2013907. https:\/\/doi.org\/10.1002\/art.27284.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1235_CR33","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13075-022-02913-8","volume":"24","author":"MM Simonds","year":"2022","unstructured":"Simonds MM, Sullivan KE, Brescia AC. Single-cell analysis reveals heterogeneity of juvenile idiopathic arthritis fibroblast-like synoviocytes with implications for disease subtype. Arthritis Res Ther. 2022;24(1):225. https:\/\/doi.org\/10.1186\/s13075-022-02913-8.","journal-title":"Arthritis Res Ther"},{"key":"1235_CR34","unstructured":"NHS-England. Clinical commissioning policy: anakinra for Haemophagocytic Lymphohistiocytosis (HLH) for adults and children in all ages [210701P] (1924). 2021."},{"issue":"2","key":"1235_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.clim.2015.06.005","volume":"160","author":"M Shimizu","year":"2015","unstructured":"Shimizu M, Nakagishi Y, Inoue N, Mizuta M, Ko G, Saikawa Y, et al. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clin Immunol. 2015;160(2):277\u201381. https:\/\/doi.org\/10.1016\/j.clim.2015.06.005.","journal-title":"Clin Immunol"},{"key":"1235_CR36","doi-asserted-by":"publisher","unstructured":"Chokshi A, Demory Beckler M, Laloo A, Kesselman MM. Paradoxical tumor necrosis factor-alpha (TNF-\u03b1) inhibitor-induced psoriasis: a systematic review of pathogenesis, clinical presentation, and treatment. Cureus. 2023;15(8):e42791. https:\/\/doi.org\/10.7759\/cureus.42791.","DOI":"10.7759\/cureus.42791"},{"issue":"8","key":"1235_CR37","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1002\/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F","volume":"43","author":"P Woo","year":"2000","unstructured":"Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43(8):1849\u201357.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1235_CR38","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/art.43401","volume":"78","author":"JB de Jonge","year":"2026","unstructured":"de Jonge JB, de Roock S, Schonenberg-Meinema D, van den Berg JM, Marshall DA, Vastert SJ, et al. Effect of time to start of biologic therapy on treatment response in childhood arthritis: results from the UCAN CAN-DU cohort. Arthritis Rheumatol. 2026;78(3):743\u201351.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"1235_CR39","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1136\/annrheumdis-2019-216843","volume":"79","author":"A Klein","year":"2020","unstructured":"Klein A, Minden K, Hospach A, Foeldvari I, Weller-Heinemann F, Trauzeddel R, et al. Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis. Ann Rheum Dis. 2020;79(7):969\u201374.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1235_CR40","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00296-018-4062-9","volume":"38","author":"P Nalbanti","year":"2018","unstructured":"Nalbanti P, Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Farmaki E, Bamidis P, et al. Juvenile idiopathic arthritis in the biologic era: predictors of the disease progression and need for early introduction of biologic treatment. Rheumatol Int. 2018;38(7):1241\u201350. https:\/\/doi.org\/10.1007\/s00296-018-4062-9.","journal-title":"Rheumatol Int"},{"issue":"6","key":"1235_CR41","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/art.34343","volume":"64","author":"CA Wallace","year":"2012","unstructured":"Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O\u2019Neil KM, Zeft AS, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64(6):2012\u201321. https:\/\/doi.org\/10.1002\/art.34343.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1235_CR42","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1093\/rheumatology\/kez577","volume":"59","author":"A Klein","year":"2020","unstructured":"Klein A, Klotsche J, Hugle B, Minden K, Hospach A, Weller-Heinemann F, et al. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry. Rheumatology (Oxford). 2020;59(9):2287\u201398. https:\/\/doi.org\/10.1093\/rheumatology\/kez577.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1235_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-018-1780-z","volume":"20","author":"J Swart","year":"2018","unstructured":"Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva Capital Ie \u0415, et al. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15, 000 patients from pharmachild and national registries. Arthritis Res Ther. 2018;20(1):285. https:\/\/doi.org\/10.1186\/s13075-018-1780-z.","journal-title":"Arthritis Res Ther"},{"key":"1235_CR44","unstructured":"NHS-England. Commissioning medicines for children in specialised services. 2024."},{"issue":"4","key":"1235_CR45","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1017\/S0266462314000464","volume":"30","author":"K Facey","year":"2014","unstructured":"Facey K, Granados A, Guyatt G, Kent A, Shah N, van der Wilt GJ, et al. Generating health technology assessment evidence for rare diseases. Int J Technol Assess Health Care. 2014;30(4):416\u201322. https:\/\/doi.org\/10.1017\/S0266462314000464.","journal-title":"Int J Technol Assess Health Care"},{"key":"1235_CR46","doi-asserted-by":"crossref","unstructured":"Hale G, Morris J, Barker-Yip J. Flexibility in assessment of rare disease technologies via NICE\u2019s single technology appraisal route: a thematic analysis. J Comp Eff Res. 2023;12(11):e230093.","DOI":"10.57264\/cer-2023-0093"},{"key":"1235_CR47","unstructured":"NICE. Guide to the methods of technology appraisal. National Institute for Health and Care Excellence. 2013."},{"issue":"3","key":"1235_CR48","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/14737167.2017.1330152","volume":"17","author":"M Paulden","year":"2017","unstructured":"Paulden M. Recent amendments to NICE\u2019s value-based assessment of health technologies: implicitly inequitable? Expert Rev Pharmacoecon Outcomes Res. 2017;17(3):239\u201342. https:\/\/doi.org\/10.1080\/14737167.2017.1330152.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"1235_CR49","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/1744666X.2023.2207823","volume":"19","author":"I Maccora","year":"2023","unstructured":"Maccora I, Land P, Miraldi Utz V, Angeles-Han ST. Therapeutic potential of JAK inhibitors in juvenile idiopathic arthritis-associated uveitis. Expert Rev Clin Immunol. 2023;19(7):689\u201392. https:\/\/doi.org\/10.1080\/1744666X.2023.2207823.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"1235_CR50","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41927-018-0010-2","volume":"2","author":"AV Ramanan","year":"2018","unstructured":"Ramanan AV, Dick AD, Jones AP, Guly C, Hardwick B, Hickey H, et al. A phase II trial protocol of tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial). BMC Rheumatol. 2018;2(1):4. https:\/\/doi.org\/10.1186\/s41927-018-0010-2.","journal-title":"BMC Rheumatol"},{"key":"1235_CR51","unstructured":"NHS-England. Clinical commissioning policy: canakinumab for patients with Still\u2019s disease refractory to anakinra and tocilizumab (adults and children 2 years and over). NHS England; 2022."},{"issue":"9","key":"1235_CR52","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1093\/rheumatology\/kev429","volume":"55","author":"L Kearsley-Fleet","year":"2016","unstructured":"Kearsley-Fleet L, Davies R, Baildam E, Beresford MW, Foster HE, Southwood TR, et al. Factors associated with choice of biologic among children with juvenile idiopathic arthritis: results from two Uk paediatric biologic registers. Rheumatology (Oxford). 2016;55(9):1556\u201365. https:\/\/doi.org\/10.1093\/rheumatology\/kev429.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1235_CR53","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198\u2013206. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202603.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1235_CR54","doi-asserted-by":"publisher","first-page":"414","DOI":"10.37765\/ajmc.2025.89774","volume":"31","author":"GC Wright","year":"2025","unstructured":"Wright GC, Okoye GA, Ehrlich AC, Lorimier DJ, Khan S, Krumbach A, et al. US health care disparities in immunology biologics access: a systematic review. Am J Manag Care. 2025;31(8):414\u201320.","journal-title":"Am J Manag Care"},{"issue":"5","key":"1235_CR55","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10067-014-2841-6","volume":"34","author":"M Al Maini","year":"2015","unstructured":"Al Maini M, Adelowo F, Al Saleh J, Al Weshahi Y, Burmester GR, Cutolo M, et al. The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases. Clin Rheumatol. 2015;34(5):819\u201329. https:\/\/doi.org\/10.1007\/s10067-014-2841-6.","journal-title":"Clin Rheumatol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-026-01235-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-026-01235-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-026-01235-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T18:32:14Z","timestamp":1785004334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12969-026-01235-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1235"],"URL":"https:\/\/doi.org\/10.1186\/s12969-026-01235-2","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was deemed exempt by the Great Ormond Street Research Ethics Committee and was carried out in accordance with local legislation and institutional requirements.","order":1,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No individual patient data was included in this paper and therefore patient consent was not required. Implied consent was obtained through voluntary completion by participants.","order":2,"name":"Ethics","label":"Consent statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"49"}}